• The delay in Modernization of the KEVEVAPI plant has affected the attainment of vaccines production targets as envisaged in MTP IV.
• The delayed finalization of the Modernization of the KEVEVAPI plant to achieve Good Manufacturing practice limits the production and productivity. Thia is also complicated by reduced demand for vaccines by the Counties.
• The lack of GMP certification limits the expanded production capacity to achieve the MTP IV targets.
• The production and distribution is mainly driven by the demands from the counties, when the demand is low the production slows down.
• The stalling of the modernization component affected the expansion of vaccines production line
• Delay finalization of the modernization of plant to a Good Manufacturing Practice (GMP) certification level
• Poor vaccination programs lacking harmonized vaccination schedules affecting the vaccine production
• No funds
• None
• inadequate provision of funds

• Provide remaining budget of KES 585 Million to finalize the Phase I of the KEVEVAPI Modernization project
• Finalize the KEVEVAPI Modernization project, harmonize and coordinate the national vaccination
• Finalize the implementation of the Modernization of the KEVEVAPI Plant which requires a budget of KES 585 Million to finalize Phase I of the project.
• Harmonize and schedule regular animal vaccinations across the control to facilitate disease control and management.
• Fund the KEVEVAPI Modernization project to attain Good Manufacturing Practice (GMP) certification at a cost of KES 585 Million to improve the efficiency and productivity.
• Allocate funds and expedite the Modernization project
• Finalize the Modernization of the plant to achieve Good Manufacturing Practice (GMP) certification to enhance productivity and access the global animal vaccines markets. Develop and implement a regular nationally coordinated animal vaccination program.
• SD for Livestock to allocate funds and expedite the project
• None
• SD for Livestock development to expedite alternative sources of funding including PPP
• timely provision of funds

• The project has experience budgetary issues during the MTP IV period. By 2023/24FY the project expenditure was KES 1,165 Million out of the Project Cost of KES 1,750 Million. The Project requires KES 585 million to finalize the Phase I of Modernization of the plant. The Good Manufacturing Practice Certification (GMP) will increase production of animal vaccine from 45 Million doses to 70 million doses annually and allow access the international markets for the vaccines. However, the production of vaccines is still ongoing at the limited capacity.
• The Production of assorted animal vaccines was 5.5 Million doses against a target of 9.25 Million doses (60%).
• The production of assorted animal vaccines is affected by the delayed Modernization of the Plant to achieve Good Manufacturing (GMP) certification. During the quarter 8.4 million doses were produced against a target of 9.25 Million (91%).
• The Production of assorted animal vaccines in Quarter II was 2.3 million doses against a target of 9.25 Million doses (25% of the target). This is affected by low demand by the counties.
• The increase of vaccines affected by the National Mass Vaccination campaign
• Lack of budget provision delayed the project implementation. The overachievement in vaccines production can be attributed to National Vaccination campaign on FMD and PPR and exports of vaccines.
• The over achievement in the quarter was attributed to the Mass National Campaign initiated by the Government
• Lack of budget provision delayed the project implementation.
• No Budgetary allocation for FY 2025/26
• No budgetary allocation
• No funding
• No Funding
• inadequate provision of funds
• project on course

No budget notes recorded.